Judge Invalidates Reissue Patent For Pfizer's Celebrex
By Brian Mahoney (March 12, 2014, 7:05 PM EDT) -- A Virginia federal judge on Wednesday invalidated a key Pfizer Inc. reissue patent covering methods for administering its blockbuster arthritis drug Celebrex, a ruling exposing the company to competition from generics makers.
U.S. District Judge Arenda L. Wright Allen said that U.S. Patent Number RE44048 was invalid under the judicial doctrine of obviousness-type double patenting, which prohibits a party from obtaining a new patent with claims that are not patentability distinct from claims in an earlier patent, according to an order granting partial summary judgment.
The New York Stock Exchange briefly halted trading of Pfizer shares shortly before the company announced...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!